BIO vs TMO vs BRKR Stock Comparison

Bio-Rad Laboratories, Thermo Fisher Scientific and Bruker Prices as of Nov 13, 2026 Peers: Industry group
BRKR Bruker Corp
$61.59 +10.8% 1M +47.4% 1Y
Market cap
$9.41B
P/E
–
Revenue (TTM)
$3.51B
Div. yield
0.32%
Life Sciences Tools Healthcare
2 wins

Head to Head

12 decided of 12

Thermo Fisher Scientific leads on 7 of the 12 questions below (Thermo Fisher Scientific 7, Bio-Rad Laboratories 3, Bruker 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBIOTMOBRKRLeader
Larger companyMarket capitalisation $9.85B $259.44B $9.41B TMO
Cheaper on earningsLower P/E, profitable companies only 9.6x 36.6x -56.1x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 36.0x 27.0x 28.0x TMO
Faster revenue growthRevenue growth, trailing twelve months +1.4% +8.3% +2.2% TMO
More profitableNet margin, trailing twelve months 39.5% 14.9% -4.8% BIO
Better return on capitalReturn on invested capital -0.6% 8.0% -1.7% TMO
Less leveragedLower net debt / EBITDA — 3.1x 10.0x TMO
Higher dividend yieldTrailing dividend yield — 0.26% 0.32% BRKR
Better 1-year returnPrice return, last 12 months +15.5% +20.7% +47.4% BRKR
Better 5-year returnAnnualised price return, 5 years -13.5%/yr +2.0%/yr -5.7%/yr TMO
Less volatileAnnualised volatility, 1 year 36.5% 30.7% 62.4% TMO
Higher overall scoreMean of the five percentile scores vs peers 70/100 60/100 48/100 BIO

Percentile Scorecard

BIOTMOBRKR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBIOTMOBRKR
Valuation 85 #38 of 243 62 #94 of 243 69 #77 of 243
Growth 48 #120 of 228 41 #136 of 228 18 #187 of 228
Profitability 70 #67 of 222 82 #40 of 222 63 #82 of 222
Financial Health 66 #85 of 248 31 #172 of 248 19 #200 of 248
Shareholder Returns 80 #32 of 158 82 #29 of 158 69 #50 of 158
Overall 70 60 48
  • BIO ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • BRKR ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBIOTMOBRKRSPY
1 month +1.0%+4.0%+10.8% -2.0%
3 months +2.8%+19.1%+6.7% -2.8%
6 months +47.9%+59.7%+43.6% +2.0%
Year to date +20.8%+20.8%+30.7% +10.6%
1 year +15.5%+20.7%+47.4% +12.2%
3 years +19.1%+52.5%-0.1% +68.1%
3 years, per year +6.0%+15.1%0.0% +18.9%
5 years -51.6%+10.2%-25.4% +61.4%
5 years, per year -13.5%+2.0%-5.7% +10.1%
10 years +119.6%+362.9%+169.3% +248.5%
10 years, per year +8.2%+16.6%+10.4% +13.3%

Risk

MeasureBIOTMOBRKRSPY
Volatility, 1Y 36.5%30.7%62.4% 13.6%
Downside volatility, 1Y 35.6%29.2%59.9% 13.9%
Beta vs S&P 500, 1Y 0.750.711.75 1.00
Return / volatility, 1Y 0.430.670.76 0.90
Max drawdown, 5Y -72.2%-41.5%-68.9% -25.4%
From 52-week high -6.2%-3.0%-7.4% -3.2%
52-week high $390.34$721.63$66.54 $779.14
52-week low $241.71$438.34$32.76 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBIOTMOBRKR
P/E now vs peer median 9.6xmedian 26.5x 36.6xmedian 26.5x -56.1xmedian 26.5x
P/S now vs peer median 3.8xmedian 2.7x 5.5xmedian 2.7x 2.7xmedian 2.7x
EV/EBITDA now vs peer median —median 18.4x 25.5xmedian 18.4x 69.3xmedian 18.4x
P/FCF now vs peer median 29.9xmedian 25.4x 34.2xmedian 25.4x 38.4xmedian 25.4x
P/B now vs peer median 1.3xmedian 2.5x 4.7xmedian 2.5x 4.1xmedian 2.5x
PEG now vs peer median 0.09median 0.98 4.84median 0.98 1.57median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBIOTMOBRKR
Revenue $2.59B $47.35B $3.51B
Gross profit $1.33B $19.45B $1.67B
Operating income -$61.90M $8.47B -$69.80M
Net income $1.02B $7.09B -$115.70M
Free cash flow $329.10M $7.60B $244.70M
R&D $265.80M $1.40B $387.20M
EPS (diluted) $37.96 $19.06 $-1.10
Cash & equivalents $465.30M $5.46B $119.70M
Total debt $1.20B $41.37B $1.71B
Shares (diluted) 26.95M 371.00M 152.50M
Enterprise value $3.46B $236.08B $8.71B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBIOTMOBRKR
P/E 9.6x 36.6x -56.1x
P/FCF 29.9x 34.2x 38.4x
P/Operating cash flow 21.0x 27.8x 27.5x
P/S 3.8x 5.5x 2.7x
P/B 1.3x 4.7x 4.1x
P/Tangible book 1.3x 7.1x 4.2x
EV/EBITDA – 25.5x 69.3x
EV/EBIT -151.6x 34.8x -157.6x
EV/Revenue 3.6x 6.2x 3.1x
EV/FCF 28.5x 38.8x 45.0x
EV/Operating cash flow 20.1x 31.6x 32.2x
PEG (3Y EPS CAGR) 0.09 4.84 1.57

Growth

14 metrics
MetricBIOTMOBRKR
Revenue growth (1Y) 1.4% 8.3% 2.2%
Revenue CAGR (3Y) -1.6% 2.9% 7.6%
Gross profit growth (1Y) -0.6% 7.8% 3.2%
Gross profit CAGR (3Y) -3.0% 4.0% 4.9%
Operating income growth (1Y) -127.6% 12.8% -209.1%
Operating income CAGR (3Y) -29.5% 7.2% -29.1%
Net income growth (1Y) 251.3% 7.9% -390.3%
Net income CAGR (3Y) 103.5% 6.2% -33.1%
EPS growth (1Y) 251.2% 9.7% -602.7%
EPS CAGR (3Y) 107.7% 7.6% -35.8%
Operating cash flow growth (1Y) -4.8% 21.9% 262.5%
Operating cash flow CAGR (3Y) 7.8% 4.5% 2.6%
Free cash flow growth (1Y) -2.3% 24.3% 2,408%
Free cash flow CAGR (3Y) 13.6% 5.1% 5.9%

Profitability

14 metrics
MetricBIOTMOBRKR
Gross margin 51.3% 41.1% 47.7%
EBITDA margin – 24.4% 4.5%
Operating margin -2.4% 17.9% -2.0%
Pretax margin 50.9% 16.7% -2.0%
Net margin 39.5% 14.9% -4.8%
FCF margin 12.7% 16.0% 7.0%
Operating cash flow margin 18.1% 19.7% 9.7%
Return on equity 13.8% 13.2% -4.9%
Return on assets 9.7% 6.2% -2.0%
Return on invested capital -0.6% 8.0% -1.7%
Return on capital employed -0.6% 8.5% -1.5%
Asset turnover 0.2x 0.4x 0.6x
Cash conversion (OCF / net income) 0.5x 1.3x -3.0x
Stock comp / revenue 2.4% 0.7% –

Financial Health

11 metrics
MetricBIOTMOBRKR
Debt / assets 11.2% 36.2% 29.4%
Debt / equity 0.2x 0.8x 0.7x
Net debt / EBITDA – 3.1x 10.0x
Debt / FCF 3.7x 5.4x 7.0x
Liabilities / assets 29.5% 52.1% 60.4%
Equity / assets 70.5% 47.9% 39.6%
Interest coverage -1.3x 12.0x -1.2x
Current ratio 3.2x 1.8x 1.8x
Quick ratio 2.2x 1.2x 0.7x
Cash ratio 1.7x 0.4x 0.1x
Altman Z-score 3.41 4.18 –

Shareholder Returns

7 metrics
MetricBIOTMOBRKR
Dividend yield – 0.3% 0.3%
Net buyback yield 0.7% 1.6% –
Shareholder yield 0.7% 1.8% 0.3%
Payout ratio (earnings) – 9.5% -26.2%
Payout ratio (FCF) – 8.9% 12.4%
Dividend growth (1Y) – 8.0% 32.3%
Dividend CAGR (3Y) – 10.1% 0.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBIOTMOBRKR
Forward P/E 36.0xFY2026 27.0xFY2026 28.0xFY2026
EPS, next fiscal year $10.18FY2026 $25.92FY2026 $2.20FY2026
EPS growth, next FY +2.6%FY2026 +13.3%FY2026 +20.2%FY2026
EPS growth, the year after -0.2% +2.2% +5.5%
Revenue, next fiscal year $2.69BFY2026 $50.12BFY2026 $3.76BFY2026
Revenue growth, next FY +4.2%FY2026 +12.5%FY2026 +9.4%FY2026
Revenue growth, the year after -7.4% -2.7% +2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBIOTMOBRKR
Held by institutions 89.5% 90.2% 93.1%
Institutions holding 405 2,627 418
Change in shares held, QoQ -2.9% +0.8% +3.6%
Institutions buying 177 1,145 249
Institutions selling 157 1,145 122
Buyers to sellers 1.13 1.00 2.04

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BIOTMOBRKR
BIO 1.00 0.59 0.48
TMO 0.59 1.00 0.62
BRKR 0.48 0.62 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BIO, TMO and BRKR?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Bio-Rad Laboratories (BIO) $9.85B, Thermo Fisher Scientific (TMO) $259.44B, Bruker (BRKR) $9.41B.

Which stock is cheaper, BIO, TMO and BRKR?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Bio-Rad Laboratories (BIO) 9.6x, Thermo Fisher Scientific (TMO) 36.6x, Bruker (BRKR) -56.1x). On next year's consensus earnings, Thermo Fisher Scientific (TMO) is cheapest (Bio-Rad Laboratories (BIO) 36.0x, Thermo Fisher Scientific (TMO) 27.0x, Bruker (BRKR) 28.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Bio-Rad Laboratories (BIO) +1.4%, Thermo Fisher Scientific (TMO) +8.3%, Bruker (BRKR) +2.2%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Bio-Rad Laboratories (BIO) 39.5%, Thermo Fisher Scientific (TMO) 14.9%, Bruker (BRKR) -4.8%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Bio-Rad Laboratories (BIO) -0.6%, Thermo Fisher Scientific (TMO) 8.0%, Bruker (BRKR) -1.7%).

Which stock has performed better?

Over the past year Bruker (BRKR) returned the most: Bio-Rad Laboratories (BIO) +15.5%, Thermo Fisher Scientific (TMO) +20.7%, Bruker (BRKR) +47.4%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Bio-Rad Laboratories (BIO) -13.5%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Bruker (BRKR) -5.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bruker (BRKR) has the highest dividend yield: Thermo Fisher Scientific (TMO) 0.26%, Bruker (BRKR) 0.32%. Bio-Rad Laboratories (BIO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Bio-Rad Laboratories (BIO) 36.5%, Thermo Fisher Scientific (TMO) 30.7%, Bruker (BRKR) 62.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BIO, TMO and BRKR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.